BioCatalystFeed / Readout calendar / FDA decisions / Drugs / Disease areas / Companies / Months
Dry eye and glaucoma clinical trials and catalysts
Active industry-sponsored trials on ClinicalTrials.gov for glaucoma: 78 (53 sponsors; 15 newly posted in the last 180 days, 2 stopped in the last 180 days; 12 new-entrant sponsors). Momentum score 10.3, rank 64 of 91 on the disease-area ranking. As of 2026-11-18.
Phase distribution: Early Phase 1 0, Phase 1 4, Phase 2 11, Phase 3 10, Phase 4 4, N/A 49.
Most active sponsors, by phase
| Sponsor | Active trials | By phase | New (window) | Upcoming readouts |
|---|---|---|---|---|
| SpyGlass Pharma, Inc. SGP | 5 | P1 1, NA 1, P3 2, P2 1 | 1 | 1 |
| Glaukos Corporation GKOS | 7 | P4 2, P2 1, NA 3, P3 1 | 1 | 2 |
| AbbVie ABBV | 3 | P4 1, P2 1, P3 1 | 0 | 0 |
| Ache Laboratorios Farmaceuticos S.A. new entrant | 1 | P3 1 | 1 | 0 |
| Amneal Pharmaceuticals, LLC AMRX | 1 | P3 1 | 0 | 0 |
| Huons Co., Ltd. | 1 | P3 1 | 0 | 0 |
| Omikron Italia S.r.l. | 1 | P3 1 | 0 | 0 |
| Santen Pharmaceutical Co., Ltd. | 1 | P3 1 | 0 | 0 |
| YS Life Science Co., Ltd. new entrant | 1 | P3 1 | 1 | 0 |
| iSTAR Medical | 6 | NA 6 | 0 | 2 |
| Iantrek, Inc. | 4 | NA 4 | 0 | 2 |
| Laboratoires Thea | 2 | P2 1, NA 1 | 0 | 0 |
| Nova Eye, Inc. NVMI | 2 | NA 2 | 0 | 1 |
| PolyActiva Pty Ltd | 2 | P1 1, P2 1 | 0 | 1 |
| Sight Sciences, Inc. SGHT | 2 | NA 2 | 0 | 1 |
| VividWhite Pty Ltd | 2 | NA 2 | 1 | 0 |
| Alcon Research ALC | 1 | NA 1 | 0 | 0 |
| Aquea Health, Inc. new entrant | 1 | NA 1 | 1 | 0 |
| Astellas Pharma Global Development, Inc. new entrant | 1 | P2 1 | 1 | 0 |
| Avisi Technologies Inc. | 1 | NA 1 | 0 | 0 |
| Bayer | 1 | NA 1 | 0 | 0 |
| BelkinVision | 1 | NA 1 | 0 | 0 |
| Centervue SpA | 1 | NA 1 | 0 | 0 |
| Ciliatech | 1 | NA 1 | 0 | 0 |
| Clinical Research Consultants, Inc. new entrant | 1 | NA 1 | 1 | 0 |
New-entrant sponsors: Ache Laboratorios Farmaceuticos S.A., YS Life Science Co., Ltd., Aquea Health, Inc., Astellas Pharma Global Development, Inc., Clinical Research Consultants, Inc..
Recently stopped trials
- NCT06577857 Sanoculis Ltd - terminated: The study was terminated following completion of the Week 24 visit. The Week 30 follow-up visit was canceled due to internal company reasons Inferonasal MIMS® Procedure: Long-Term Follow-Up Extension Study
- NCT06465537 Shanghai BDgene Co., Ltd. - suspended: Per the requirement of China regulation. CRISPR/Cas9 Instantaneous Gene Editing Therapy to Intraocular Hypertensive POAG With MYOC Mutation
Upcoming trial readouts (next 90 days)
| Readout | Phase | Sponsor | Trial | Conditions | Status | Enrollment |
|---|---|---|---|---|---|---|
| 2026-12 est. | P2/P3 | Oculis OCS | NCT07548632 A Clinical Study Evaluating Licaminlimab for Dry Eye Disease | Dry Eye Disease (DED) | active not recruiting | 160 |
| 2026-12-27 est. | P2 | Dompé Farmaceutici S.p.A | NCT07503886 An Exploratory Efficacy and Safety Study of DFL24498 Topical Ophthalmic Solution Compared With Vehicle in Participants With Dry Eye Disease | Dry Eye Disease (DED) | recruiting | 417 |
| 2027-01 est. | P1/P2 | EyeD Pharma | NCT07036510 Safety and Efficacy of TimoD Sustained-Release Implant in Participants With Glaucoma or Ocular Hypertension Undergoing Cataract Surgery | Glaucoma; Ocular Hypertension | recruiting | 42 |
| 2027-01-21 est. | P2 | Laboratoires Thea | NCT07169695 A Study to Compare the Effectiveness and Safety of T1695 Versus Ciclosporin in Participants With Moderate to Severe Vernal Keratoconjunctivitis | Moderate to Severe Vernal Keratoconjunctivitis | recruiting | 120 |
| 2027-02 est. | P2 | Bausch & Lomb Incorporated BLCO | NCT07778888 BL1107 Response and Intensity Guided Dosing for Hyperemia Resolution Trial | Dry Eye Disease | recruiting | 20 |
Readouts in the last 180 days
| Readout | Phase | Sponsor | Trial | Conditions | Status | Enrollment |
|---|---|---|---|---|---|---|
| 2026-11-15 est. | P2 | PolyActiva Pty Ltd | NCT06964191 Evaluate Efficacy and Safety of PA5108 Ocular Implants in Primary Open Angle Glaucoma or Ocular Hypertension | Glaucoma, Open-Angle; Ocular Hypertension | active not recruiting | 75 |
| 2026-11 est. | P2 | BRIM Biotechnology Inc. | NCT07078955 A Dose Regimen Study of BRM421 Ophthalmic Solution in Patients With Dry Eye Disease | Dry Eye Disease (DED); Keratoconjunctivitis Sicca | not yet recruiting | 99 |
| 2026-10-01 | P2 | Qlaris Bio, Inc. | NCT07354477 Single-site Pilot Study Evaluating the Effect of QLS-111 Ophthalmic Solution on Posterior Perfusion and Vessel Dilation | Non-proliferative Diabetic Retinopathy (NPDR); Open-angle Glaucoma (OAG); Normal Tension Glaucoma (N | completed | 9 |
| 2026-10 est. | P2 | Taejoon Pharmaceutical Co., Ltd. | NCT07810972 Evaluate the Safety and Efficacy of TJO-087 | Dry Eye Syndrome (DES) | active not recruiting | 90 |
| 2026-09 est. | P2 | Vanda Pharmaceuticals VNDA | NCT07179055 An Eight-Week Study to Evaluate the Safety and Efficacy of VSJ-110 Compared to Placebo in the Treatment of Dry Eye | Dry Eye | recruiting | 160 |
| 2026-08-31 est. | P3 | Santen Pharmaceutical Co., Ltd. | NCT06666855 A Phase III Study in Subjects With Primary Open Angle Glaucoma or Ocular Hypertension in China | Open Angle Glaucoma; Ocular Hypertension | active not recruiting | 345 |
| 2026-08-21 | P3 | AbbVie ABBV | NCT07284381 A Clinical Study to Evaluate the Effect and Side Effect of a New Artificial Tear Formulation (ABBV-444) Compared to Refresh Optive Unit Dose in Adult Participan | Dry Eye Disease | completed | 261 |
| 2026-07-22 | P2/P3 | Qlaris Bio, Inc. | NCT07354516 Study of QLS-111-FDC in Open-Angle Glaucoma or Ocular Hypertension | OAG - Open-Angle Glaucoma; OHT - Ocular Hypertension | completed | 64 |
| 2026-06-19 | P3 | AbbVie ABBV | NCT03891446 Long-term Safety and Efficacy Extension Trial of Bimatoprost SR | Open-Angle Glaucoma; Ocular Hypertension | completed | 455 |
| 2026-05-28 | P2 | Bausch & Lomb Incorporated BLCO | NCT07128628 A Study Evaluating the Safety and Efficacy of a Fixed-Dose Combination for Dry Eye Disease | Dry Eye Disease | completed | 443 |
Landscape counts: ClinicalTrials.gov, industry lead sponsors, active statuses, via the free hosted BioCatalystFeed MCP tool condition_landscape (query "glaucoma"); readouts matched by condition text. Registry counts only; not a forecast.
Readout = ClinicalTrials.gov primary completion date (sponsor-reported; est. dates often slip; top-line
results usually follow weeks to months later). FDA events: PDUFA dates are extracted from company 8-K filings (SEC EDGAR) and are
company-disclosed and UNVERIFIED - read the filing; AdCom meetings come from Federal Register notices; approvals from Drugs@FDA
(openFDA); complete response letters from openFDA (published with a lag). Tickers are matched by name with a confidence score.
Generated 2026-11-18T17:57:33Z. Same data: bcf readouts search, bcf fda-decisions search, MCP
readout_calendar / fda_decisions. Not investment advice.